Thomas Stankovich - 24 Jan 2023 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Issuer symbol
RSLS
Transactions as of
24 Jan 2023
Net transactions value
-$3,708
Form type
4
Filing time
07 Mar 2023, 15:11:11 UTC
Previous filing
20 Dec 2022
Next filing
06 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Sale $360 -48 -0.74% $7.49 6,461 24 Jan 2023 Direct F1, F2
transaction RSLS Common Stock, $0.001 par value per share Sale $824 -110 -1.7% $7.49 6,351 24 Jan 2023 Direct F1, F2
transaction RSLS Common Stock, $0.001 par value per share Sale $2,087 -157 -2.5% $13.29 6,194 02 Feb 2023 Direct F1, F2
transaction RSLS Common Stock, $0.001 par value per share Sale $438 -103 -1.7% $4.25 6,091 28 Feb 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units (as adjusted for a reverse stock split, see footnote (2) below), all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.
F2 On December 23, 2022, ReShape effected a 1-for-50 reverse stock split of its issued and outstanding common stock.